# Villanelle Life

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/villanelle-life

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Series A (Jan 27, 2026)
- Investors on record: 1

## About

Established in 2021 and based in Shanghai, China, Shanghai Xuanyan Biotechnology Co., Ltd., trading as Villanelle Life, is a biopharmaceutical company that develops platforms for cancer and cardiovascular drugs including early diagnosis, screening, and pharmaceuticals. is a biopharmaceutical company that develops platforms for cancer and cardiovascular drugs including early diagnosis, screening, and pharmaceuticals. 90% of the company's team members hold PhDs and have experience working in leading healthcare organizations. The company also owns more than 10 patents in China and the US, including 10 patents for companion diagnostic products, and has published more than 20 academic papers with a combined impact factor of more than 200. In January 2026, Villanelle Life raised a series A funding from new investor Detong Capital.

The company utilizes exclusive AI algorithms and bioinformatics analysis technology to build an AI new drug target mining platform, forming an integrated layout from upstream target and marker discovery to downstream drug, early screening, and assisted diagnosis development. Specific products include monoclonal antibody drug INTX-001 and anti-X monoclonal antibody INTX-002.

The company's revenue is generated by providing AI drug, early screening, & companion diagnostic platforms.

## Funding rounds

- Series A, Jan 27, 2026 — Detong Capital

## Investors

- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series A